Form Approved

OMB No. 0920-1359

Expiration Date: 12/31/2024

National Syringe Services Program Evaluation

Survey Year 1

Privacy Act Statement:

This information is collected under the authority of the Public Health Service Act, Section 301, "Research and Investigation," (42 U.S.C. 241); and Sections 304, 306 and 308(d) which discuss authority to maintain data and provide assurances of confidentiality for health research and related activities (42 U.S.C. 242 b, k, and m(d)). This information is also being collected in conjunction with the provisions of the Government Paperwork Elimination Act and the Paperwork Reduction Act (PRA). This information will be used by the Centers for Disease Control and Prevention (CDC) with the support of the University of Washington, the North American Syringe Exchange Network, and New York University in order to help build a stable foundation for SSP monitoring and establish a system for program improvement, and ensure quality service delivery at SSPs nationwide.

Public reporting burden of this collection of information is estimated to average 35 minutes, including the time for reviewing instructions, administering/reading questions, and entering responses. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-New)

DAVE PURCHASE MEMORIAL SURVEY QUESTIONNAIRE SECTIONS

Contents

Abbreviations	2
Key Terms	2
PRELIMINARY INFORMATION	
PROGRAM CHARACTERISTICS	5
CLIENT CHARACTERISTICS	
COMMUNITY RELATIONS AND CHALLENGES	
SYRINGE COLLECTION, DISTRIBUTION, AND DISPOSAL	
PROVISION OF NALOXONE AND OTHER OVERDOSE REVERSAL MEDICATIONS	
PROVISION OF SERVICES	
2020 MODULE	25
PROCESS EVALUATION	

OVERVIEW

Abbreviations

R Respondent

DK Don't know

REF Refused to answer

NA Not applicable (question asked of R but this is a codable response option)

EQ Equal to Greater than

GE Greater than or equal to LEss than or equal to

LT Less than
NE Not equal to

Key Terms

Term	Prefix / format	Definition
Calculated variable	CALC_	Item identifier (not prefix for variable name) for variables calculated by the CAPI program that appear in the CRQ.
Message	INTERVIEWER:	Message displayed to the interviewer that is <u>not</u> to be read to R. May be triggered by an edit check. Distinct from Interviewer Instruction. 'FIELD NOTE' indicates instructions that will be added as a field note rather than directly included in the question.
Filter question		A question that determines whether the respondent should receive subsequent question or set of questions, typically on a related topic.
Logic Check	Check_	Logic that must be checked (by the CAPI program) in order to determine proper routing to the next item in the CAPI programmed questionnaire.
Interviewer instruction		Instruction to interviewer regarding survey administration. Standard instructions are 'Give Respondent Flashcard {letter}', 'READ choices', 'DO NOT READ choices', & 'CHECK ALL that apply'.
Introductory statement	INTRO_	Transitional statement read to R at the beginning of a new topic (e.g., Section, set of questions, etc.). Prefix is followed by section abbreviation, series, or first item in set to which it applies.
Range		Range of valid response values for items collecting or computing numeric data. E.g., the valid range of responses to number of sex partners in past 12 months is 0 to 7000.
Section		Section of the Questionnaire. Each section has a unique two letter abbreviation.
Soft Edit Check	SoftEdit_	A check to determine whether the response entered is implausible. If yes, CAPI program displays message to interviewer; program may advance after closing the error message dialog box.

DAVE PURCHASE MEMORIAL SURVEY PRELIMINARY INFORMATION

INTRO_OMB.

Public reporting burden of this collection of information is estimated to average 35 minutes per survey, including the time for reviewing instructions, administering questions and entering responses. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, US8-4, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-New).

CALC YR

Hidden variable: Year of recall period. This is the period that the participant will be asked to recall throughout the survey. This needs to be updated manually by survey staff each time the survey is administered.

Field note: Must be 4 digits.

YEAR

Recall year

PI1. Are you completing this survey by yourself or by speaking with an interviewer?

ADMIN

Mode of administration

Check_INTRO.

If R self-administering survey (PI1 [ADMIN] EQ 0), go to INTRO_SA.

Else, go to INTRO_IA.

INTRO_SA.

Thank you for taking the time to complete this program survey.

When answering questions, please refer to the period from January 1, [YEAR], to December 31, [YEAR] unless otherwise stated. If program data are not available, please use your best estimate to complete the questions below. If your program only operated during some of the specified time period, please provide information reflective of the time period(s) during which your program did operate.

If you need any clarifications about any of the questions in this survey or how this information will be used, please contact [project coordinator name, phone, email].

If you need to step away, <u>PLEASE REMEMBER TO SAVE YOUR SURVEY</u>, as not saving it will result in losing your responses. To save, first click on the save button at the bottom of the screen. You will then be prompted to enter an <u>email address</u> and a link will be sent to you to continue the survey later.

INTRO_IA.

Thank you for taking the time to complete this program survey.

When answering questions, please refer to the period from January 1, [YEAR], to December 31, [YEAR] unless otherwise stated. If program data are not available, please use your best estimate to complete the questions below. If your program only operated during some of the specified time period, please provide information reflective of the time period(s) during which your program did operate.

If you need any clarifications about any of the questions in this survey or how this information will be used, please

let me know.

During the survey, you may need to refer to your records to answer some questions. If you are unable to answer a question today, but later find the answer in your records, you can reach us later to provide this additional information by contacting [project coordinator name, phone, email].

CALC_SDATE

Automatic, hidden variable: Survey date (today)

Automatic start date

__/__/

CALC_START

Automatic, hidden variable: Start time of survey

Preliminary information: Start time

__:__

What is the name of your program?

PI2. [FIELD NOTE: IF REFUSED, LEAVE BLANK]

PROGNAM Name of program

{text response; max characters = 100}

What month and year did the program start? Start by selecting the month. If you do not remember the exact month, please provide your best estimate.

SDATE_M

PI3a.

SDATE month

SEATE MONEY	
January	1
February	2
March	3
April	4
May	5
June	6
July	7
August	
September	
October	
November	11
December	
Don't Know	
Refuse to Answer	

PI3b. Enter the year. If you do not remember the exact year, please provide your

best estimate.

Please enter four digits.

SDATE_Y	[FIELD NOTE: IF REFUSED OR DON'T KNOW, LEAVE BLANK] SDATE year
SDATE_I	
	Range
SoftEdit_SDATE_Y	If [SDATE_Y] > [YEAR], then display error message: "The year the SSP started is later than [YEAR]. Please confirm
	that this year is accurate."
INTRO_PI.	First, we would like to ask a series of questions about your program and the services your program provided between January 1, [YEAR], and December 31, [YEAR]. Following these questions, we will then ask a few of the same questions about 2020. The COVID-19 pandemic likely impacted program operations and services provided by programs nationwide during 2020, so this information will be extremely important to help understand these impacts and the continuing challenges to programs moving forward.
PI4.	Did your program provide any services at <u>any time</u> between January 1, [YEAR], and December 31, [YEAR]?
OPRCL	Operated during recall period No
	Yes
Check_PI4.	If R did not operate at any time during the recall period (PI4 [OPRCL] EQ 0), go to INTRO_MD1. Else, go to INTRO_PC.
	PROGRAM CHARACTERISTICS
INTRO_PC.	The next set of questions is about your program background and overall set-up. All information is important, and we appreciate your time and effort in completing this survey. However, we understand if you cannot answer some of
	these questions; in these situations, you have an option to select "don't know" or "refuse to answer" responses, whichever best applies.
S_TIME1	Automatic hidden variable: Respondent start time
	Respondent start time
	:
	Was your program operated by a
PC1.	Select all that apply.
OPBY	Program operator Community-based organization
	Community-based organization City health department
	County health department
	State health department

Health care organization.....

	Academic institution or hospital
	Volunteers only
	Other (please specify)
	Refuse to Answer
Check_PC1spec.	If R selected 'Other (please specify)' (PC1(7) [OPBY(7)] EQ 1), go to PC1spec [OPBY_S].
	Else, go to PC2 [SFUND].
PC1spec.	Specify other program operator.
OPBY_S	Specify other program operator
	{text response; max characters = 100}
	What were your program's sources of funding?
PC2.	Select all that apply.
SFUND	Sources of funding
	City government
	County government
	State government
	Federal government
	Non-profit foundation/organization
	Individual donations
	Personal funds from program managers or staff
	Corporate donation
	Other (please specify)
	Don't Know99
	Refuse to Answer
Check_PC2spec.	If R selected 'Other (please specify)' (PC2(9) [SFUND(9)] EQ 1), go to PC2spec [SFUND_S].
	Else, go to PC3 [BUDGET].
PC2spec.	Specify other source of funding.
SFUND_S	Specify other funding source
31	Specify other randing source
	{text response; max characters = 100}
	What was your total program budget? If your program is part of a larger, multi-service organization, please only
PC3.	provide the budget for your part of the program. Please provide the best estimate to your knowledge.
BUDGET	Total program budget
	Less than \$25,000
	\$25,000-\$100,000
	\$100,001-\$250,000
	\$250,001-\$500,0004
	\$500,001-\$1 million
	Between \$1 million and \$2 million
	\$2 million or more
	Don't Know99

PC4.	Did your program employ any full-time paid staff (tha	t is those wealing 20 hours now week as move)?		
FTSTAF	Full-time paid staff	it is, those working so hours per week or more):		
TISIAI	No	0		
	Yes.			
	Refuse to Answer			
	Neruse to Allswer	,		
		nerly or currently injected drugs? Include paid outreach		
PC5.	workers and those paid with stipends or salaries.			
PWIDST	Current or former PWID staff			
	No			
	Yes	_		
	Don't Know	9		
	Refuse to Answer	7		
PC6.	Did your program have any volunteers who formerly	or currently injected drugs? Include outreach volunteers.		
PWIDVL	Current or former PWID volunteers			
	No	0		
	Yes	1		
	Don't Know	9		
	Refuse to Answer	7		
	What were your program's total hours of operation i	n a typical week? If your program had more than one location		
		eration for the overall program. For example, if your program		
		days per week, that would be 20 hours, not 60 hours, of		
PC7.		r prefer not to answer, you may leave the response blank.		
NUMHRS	Number of hours per week			
	·			
	— — — Range	0-168		
	-			
INTRO_GEO.		services programs, please enter the state and county(ies)		
	where your program operates. If your program has multiple locations, please list counties for all locations. Please			
	also consider mobile units in your responses.			
5-0	Please specify the state(s) or territory(ies) where you	r program is		
PC8a.	located: Select all that apply.			
SSPSTAT	State(s) or territory(ies)			
	Alabama			
	Alaska			
	Arizona			
	Arkansas			
	California			

 Colorado
 .08

 Connecticut
 .09

 Delaware
 .10

District of Columbia	11
Florida	12
Georgia	13
Hawaii	15
ldaho	16
Illinois	
Indiana	
lowa	
Kansas	
Kentucky	
Louisiana	
Maine	
Maryland	
Massachusetts	
Michigan	
Minnesota	
Mississippi	
Missouri	
Montana	
Nebraska	
Nevada	
New Hampshire	
New Jersey	
•	
New Mexico	
New York	
North Carolina	
North Dakota	
Ohio	
Oklahoma	
Oregon	
Pennsylvania	
Puerto Rico	
Rhode Island	
South Carolina	.45
	46
Tennessee	
Texas	
US Virgin Islands	7.8
Utah	49
Vermont	50
Virginia	
Washington	
West Virginia	54
Wisconsin	55
Wyoming	5.6
Refuse to Answer	77

In which counties does your program provide services? Please include brick and mortar locations, mobile services, deliveries, and other ways you provide services. If you do not know or prefer not to answer, you may leave the response blank.

PC8b.

SSPCNTY County(ies)

PC9. local SRVAREA Serv Urba Subu Rura	your program serve communities that you would consider urban, suburban, or rural? Please consider all the ations in which your program operates and select all that apply. vice area type
PC9. local SRVAREA Serv Urba Subu Rura	itions in which your program operates and select all that apply. vice area type
SRVAREA Serv Urba Subu Rura	rice area type
Urba Subu Rura	**
Subu Rura	an
Rura	
	urban
Rafu	al
Ketu	use to Answer
Uau	
	v did your program deliver services? If your program had more than one location or service delivery type, select
	hat apply.
	rice delivery type
	k and mortar building/storefront
	pile unit, such as an RV, van, or car
	t or outdoor area
	ne delivery
	ckpack" delivery
	l order
•	nge vending machine
Othe	er (please describe)
Don	't Know99
Refu	use to Answer
Check_PC10spec. If R	R selected 'Other (please describe)' (PC10(8) [SDELIV(8)] EQ 1), go to PC10spec [SDELIV_S].
Else	e, go to PC11 [DSRPT].
PC10spec. Spec	cify other service delivery type.
	cify other service delivery type
{text	t response; max characters = 100}
Did	your program have to stop providing services for any period of time between January 1, [YEAR], and December
	[YEAR] (that is, you did not provide services for at least one day or more when you had expected to be open)?
	providing services
•	5 providing services 0
	't Know
кети	use to Answer
Check_PC12. If R	R had to stop providing services (PC11 [DSRPT] EQ 1), go to PC12 [WHYDSRP]. Else, go to PC13 [INEVAL].

Please choose the reason(s) for the disruption.
PC12. Select all that apply.

WHYDSRP	Why services disrupted
	Inadequate funding for materials or supplies
	Inadequate funding for operations
	Lack of personnel to staff the program
	Legal or political intervention
	COVID-19 pandemic
	Other (please describe)
	Don't Know9
	Refuse to Answer
Check_PC12spec.	If R selected 'Other (please describe)' (PC12(6) [WHYDSRP(6)] EQ 1), go to PC12spec [WHYDSRP_S].
oncok_r ozzapeci	Else, go to PC13 [INEVAL].
PC12spec.	Specify other reason for disruption(s) to services.
WHYDSRP_S	Specify other disruption
	{text response; max characters = 100}
PC13.	Did your program review your program's data for monitoring or evaluation purposes between January 1, [YEAR], and December 31, [YEAR]?
INEVAL	Did program review internal data
INEVAL	No
	Yes
	Refuse to Answer
	Refuse to Answer
PC14.	What computer software program did you use to manage your program's data? Select all that apply.
SFTWR	Software to manage client data
	None
	Excel
	Access
	Neo360
	REDCap
	Qualtrics
	SurveyMonkey
	Other (please describe)
	Refuse to Answer
Check_PC14spec.	If R selected 'Other (please describe)' (PC14 [SFTWR] EQ 8), go to PC14spec [SFTWR_S].
	Else, go to PC15 [UNIQID].
PC14spec.	Specify other software used to manage client data.
SFTWR_S	Specify other software
	{text response; max characters = 100}

PC15. Did your program assign each client a unique ID?

UNIQID	Did program assign unique ID					
	No	0				
	Yes	1				
	Refuse to Answer	-				
	Refuse to Allswer					
	How many unique clients did your program serve? Please					
PC16.	not know or prefer not to answer, you may leave the resp	onse blank.				
NUMCLI	Number of unique clients					
	Range	0-99999999				
	Did your program have residency restrictions on who coul	d access services, that is, only people from certain				
PC17.	geographic locations could receive services from your pro					
RESRSTR	Residency restrictions					
	, No	0				
	Yes					
	Don't Know					
	Refuse to Answer					
	Refuse to Allswei					
	Did your program require clients to provide identifying do	cuments (for example, a driver's license) to enroll or				
PC18.	receive services?					
IDDOC	Require identifying documents					
	No	0				
	Yes					
	Don't Know					
	Refuse to Answer					
		······································				
	CLIENT CHARACTERISTIC	es s				
INTRO_CC.	The next questions are about the characteristics of the clie these questions, please think about your program's operat [YEAR].					
CC1.	Which demographic groups did your program reach in [YE	AR]? Select all that apply.				
DEMSRV	Demographic groups served					
	Cisgender women					
	Cisgender men					
	Transgender women					
	Transgender men					
	Genderqueer/non-binary persons					
	American Indian or Alaska Native persons					

	wnite persons
	Persons aged <18 years
	Persons aged 18 to 29 years
	Persons aged 30 to 39 years
	Persons aged ≥40 years
	Lesbian, gay, bisexual, or queer persons
	Other (please describe)
	Refuse to Answer
Check_CC1spec.	If R selected 'Other (please describe)' (CC1 [DEMSRV] EQ 16), go to CC1spec [DEMSRV_S].
	Else, go to CC2 [DEMRCH].
CC1spec.	Specify other demographic group reached.
DEMSRV_S	Specify other group
_	
	{text response; max characters = 100}
	Which down and it was a little and the little and t
550	Which demographic groups in your community did your program have difficulty reaching in [YEAR]? Select all that
CC2.	apply.
DEMRCH	Difficulty reaching demographic groups
	Cisgender men
	Cisgender women
	Transgender men
	Transgender women
	Genderqueer/non-binary persons
	American Indian or Alaska Native persons
	Asian persons
	Black or African American persons
	Hispanic or Latinx persons
	Native Hawaiian or Other Pacific Islander persons
	White persons
	Persons aged <18 years
	Persons aged 18 to 29 years
	Persons aged 30 to 39 years
	Persons aged ≥40 years
	Lesbian, gay, bisexual, or queer persons
	Other (please describe)
	Refuse to Answer
	Netuse to Answer
Check_CC2spec.	If R selected 'Other (please describe)' (CC2 [DEMRCH] EQ 16), go to CC2spec [DEMRCH_S].
	Else, go to CC3 [DEMRCH].
	Specify other demographic group your program had difficulty
CC2spec.	reaching.
DEMRCH_S	Specify other group
_	
	{text response; max characters = 100}

Native Hawaiian or Other Pacific Islander persons.....

	Approximately what percentage of your clients did	not have he	ealth insuranc	e? Please ι	se your re	cords if av	ailable
CC3.	but provide your best estimate if no records are kep	ot or are not	t readily avail	able.			
INSUR	Client insurance						
	Less than 25%			1			
	25-50%			2			
	51-75%						
	More than 75%						
	Don't Know						
	Refuse to Answer						
	Refuse to Aliswei	***************************************		/			
	For each of the following substances, please indicate		=				_
004	each substance on a weekly or more frequent basis	. Please use	your records	if available	but provi	ae your be	est estimate
CC4.	if no records are kept or are not readily available.						
INJDRUG	Substances injected by clients						
		Less			More		
		than			than	Don't	Refuse to
	None	25%	25-50%	51-75%	75%	Know	Answer
INJDRUGA	Heroin, by itself		•••••				
INJDRUGB	Speedball, which is heroin and cocaine						
	together						
INJDRUGC	Goofball, which is heroin and						
	methamphetamine together						
INJDRUGD	Methamphetamine, by itself, also known						
	as meth or speed						
INJDRUGE	Fentanyl, by itself or in combination with						
	other drugs						
INJDRUGF	Powder cocaine, by itself						
INJDRUGG	Crack cocaine, by itself						
INJDRUGH	Painkillers, such as Oxycontin, Dilaudid, or						
	Percocet						
INJDRUGI	Benzodiazepines or other downers, such						
	as Valium, Xanax, or Klonopin						
INJDRUGJ	Other 1 (please describe)						
INJDRUGK	Other 2 (please describe)						
INJDRUGL	Other 3 (please describe)						
	,						
Check_CC4specA.	If R selected 'Other 1 (please describe)' (CC4 [INJDR	UGJ1), go to	CC4specA [IN	NJDRUGJ S1			
	Else, go to Check CC4specB.	1770		1			
	, 80 to oliooiee iebeez.						
	From the previous question, specify 'Other 1' substa	nco iniocto	4				
CC4specA.		ince injecte	u				
-	by clients.						
INJDRUGJ_S	Specify other substance injected						
	(but was a second secon						
	{text response; max characters = 100}						
Check_CC4specB.	If R selected 'Other 2 (please describe)' (CC4 [INJDR	UGK]), go to	CC4specB [II	NJDRUGK_S].		

Else, go to Check_CC4specC.

CC4specB.	From the previous question, specify 'Other 2' substance injected by clients.
INJDRUGK_S	Specify other substance injected
	{text response; max characters = 100}
Check_CC4specC.	If R selected 'Other 3 (please describe)' (CC4 [INJDRUGL]), go to CC4specC [INJDRUGL_S]. Else, go to INTRO_CR.
CC4specC. INJDRUGL_S	From the previous question, specify 'Other 3' substance injected by clients. Specify other substance injected
	COMMUNITY RELATIONS AND CHALLENGES
INTRO_CR.	The next questions are about your program's relationships with members of the community and any related challenges. As a reminder, as you answer these questions, please think about your program's operations between January 1, [YEAR], and December 31, [YEAR].
CR1. SUPADV	Which individuals or types of organizations advocated for your program or provided any type of support? Select all that apply. Sources of support or advocacy Local health officials
Check_CR1spec.	If R selected 'Other (please describe)' (CR1(8) [SUPADV(8)] EQ 1), go to CR1spec [SUPADV_S]. Else, go to CR2 [CHLNG].

CR1spec. Specify other source of support SUPADV_S Specify other source of support

	{text response; max characters = 100}
	What types of <u>external</u> challenges did your program face, not including challenges related to funding? Select all
CR2.	that apply.
ECHLNG	Types of external challenges
	Limited/no law enforcement support
	Active police harassment/arrest of program clients
	Program operations disrupted by government or law
	enforcement
	Local policy/law that restricts program services
	Lack of support from local health officials
	Lack of community support
	Active community harassment
	COVID-19 pandemic
	Other (please describe)
	Did not face external challenges
	Refuse to Answer
Check_CR2spec.	If R selected 'Other (please describe)' (CR2(9) [ECHLNG(9)] EQ 1), go to CR2spec [ECHLNG_S].
Check_ck2spec.	Else, go to CR3 [ICHLNG].
	LISE, go to CK3 [ICHENG].
CR2spec.	Specify other external challenges
ECHLNG_S	Specify other external challenges
20.12.10_0	open, end one out of the open
	{text response; max characters = 255}
CR3.	What types of internal challenges did your program face? Select all that apply.
ICHLNG	Types of internal challenges
	Staff burnout
	Staff shortage
	Limited/no funding
	Limited/no resources or supplies (other than funding)
	Other (please describe)
	Did not face internal challenges
	Refuse to Answer
Check_CR3spec.	If R selected 'Other (please describe)' (CR3(5) [ICHLNG(5)] EQ 1), go to CR3spec [ICHLNG_S].
erieck_enospec.	Else, go to CR4 [RLHO].
	LISC, BU TO CK4 [KEITO].
CR3spec.	Specify other internal challenges
ICHLNG_S	Specify other internal challenges
	{text response; max characters = 255}

How would you describe your program's relationship with your local health department(s)?

CR4.

RLHO	Relationship with local health officials	
	Very good	1
	Somewhat good	
	Neither good nor poor	
	Somewhat poor	
	Very poor	
	Nonexistent	
	Refuse to Answer	
	Refuse to Allswer	
CR5.	How would you describe your program's relationship with law enforc	cement?
		ement:
RLAW	Relationship with law enforcement	4
	Very good	
	Somewhat good	
	Neither good nor poor	
	Somewhat poor	
	Very poor	
	Nonexistent	
	Refuse to Answer	7
	SYRINGE COLLECTION, DISTRIBUTION, AND DISPO	DSAL
INTRO_SYR.	The next set of questions pertain to syringe services provided by your	program between January 1, [YEAR], and
	December 31, [YEAR].	
	11	Diaman and the combant of the combands
CVD4	How many total sterile syringes did your program provide to clients?	Please provide your pest estimate it records
SYR1.	. 19 9111 16 1 11 6 11	
NUMSYR	are not readily available. If you do not know or prefer not to answer,	
	are not readily available. If you do not know or prefer not to answer, Number of sterile syringes provided	
	Number of sterile syringes provided ———————————————————————————————————	you may leave the response blank.
		you may leave the response blank.
	Number of sterile syringes provided ———————————————————————————————————	you may leave the response blank.
	Number of sterile syringes provided — — — — — — — Range	you may leave the response blank. D.9999999
SYR2.	Number of sterile syringes provided — — — — — — — Range	you may leave the response blank. D.9999999
SYR2. CLINEED	Number of sterile syringes provided — — — — — — — Range	you may leave the response blank. D.9999999
	Number of sterile syringes provided — — — — — — — Range	you may leave the response blank. 0-9999999 eds, without any restrictions?
	Number of sterile syringes provided — — — — — — — Range — — — — — — — — — — — — — — — — — — —	you may leave the response blank. 0-9999999 eds, without any restrictions?
	Number of sterile syringes provided — — — — — — — Range	you may leave the response blank. 09999999 eds, without any restrictions?
	Number of sterile syringes provided ———————— Range	you may leave the response blank. 09999999 eds, without any restrictions?
	Number of sterile syringes provided ———————— Range	you may leave the response blank. 09999999 eds, without any restrictions?
	Number of sterile syringes provided ———————— Range	you may leave the response blank. 0-9999999 eds, without any restrictions?
	Number of sterile syringes provided ———————— Range	you may leave the response blank. 0-9999999 eds, without any restrictions?
CLINEED	Number of sterile syringes provided ——————— Range	you may leave the response blank. 0-9999999 eds, without any restrictions?
CLINEED SYR3.	Number of sterile syringes provided ——————————————————————————————————	you may leave the response blank. 0.9999999 eds, without any restrictions?
CLINEED SYR3.	Number of sterile syringes provided ——————————————————————————————————	you may leave the response blank. 0::99999999 eds, without any restrictions?
CLINEED SYR3.	Number of sterile syringes provided ——————— Range	you may leave the response blank. 099999999 eds, without any restrictions?
CLINEED SYR3.	Number of sterile syringes provided ——————————————————————————————————	you may leave the response blank. 099999999 eds, without any restrictions?
CLINEED SYR3.	Number of sterile syringes provided ——————— Range	you may leave the response blank. 099999999 eds, without any restrictions?

	Else, go to INTRO_PN.
	Did your program provide training or other support for clients to distribute new, sterile syringes to others (i.e.,
SYR4.	secondary exchange) and/or facilitate syringe disposal?
SETRAIN	Secondary exchange training
	No
	Yes
	Refuse to Answer
	PROVISION OF NALOXONE AND OTHER OVERDOSE REVERSAL MEDICATIONS
INTRO_PN.	In this section, we will ask you about overdose prevention services your program may have provided, such as
_	overdose prevention training and naloxone distribution. As a reminder, we are asking about services provided by
	your program between January 1, [YEAR], and December 31, [YEAR].
PN1.	What overdose prevention or treatment services did your program provide? Select all that apply.
WHATOD	What OD prevention or treatment services provided
	None
	Naloxone kits
	Naloxone prescription
	Fentanyl test strips
	Overdose prevention and response training for opioids
	Overdose prevention and response training for drugs other
	than opioids (e.g., cocaine, methamphetamine)
	Refuse to Answer
	Refuse to Aliswel
cl l pulo	ICD 11 1 1 1 1
Check_PN2.	If R provided naloxone kits (PN1 [WHATOD] EQ 1), go to PN2 [NALKIT].
	Else, go to INTRO_PS1.
	How many naloxone kits were distributed by your program? Please provide the number of kits distributed
	regardless of how many doses were contained in each kit. If your program does not collect these data, please
	provide your best estimate. If you do not know or prefer not to answer, you may leave the response blank.
PN2.	
NALKIT	Number of naloxone kits distributed
	Range0-9999
	How many doses were distributed in each naloxone kit by your program? If you do not know or prefer not to
	answer, you may leave the response blank.
PN3.	
NALDOS	Number of doses distributed in each naloxone kit

PN4. NALDIS	In what ways did your program distribute naloxone kits? Select all that apply. How distributed naloxone Direct distribution from staff to client
PN5. BARNAL	What barriers, if any, did your program experience in providing naloxone to your clients? Select all that apply. Barriers to providing naloxone No barriers
Check_PN5spec.	If R selected 'Other (please describe)' (PN5(5) [BARNAL(5)] EQ 1), go to PN5spec [BARNAL_S]. Else, go to INTRO_PS1.
PN5spec. BARNAL_S	Specify other barrier in providing naloxone Specify other barrier in providing naloxone [text response; max characters = 255]
	PROVISION OF SERVICES

INTRO PS1.	The next set of questions are about the services your program provided or needed between January 1, [YEAR], and
_	December 31, [YEAR]. This information will help us understand the services that programs are already providing, trying to expand, or adding to meet client needs. Please indicate next to each service whether your program 1) <i>fully</i>
	provided the service (that is, the service was provided at a level that fully met client needs), 2) partially provided the
	service (that is, the service was provided inconsistently or at a level that did not meet client needs), 3) did not provide the service and was not able to meet client needs, or 4) did not provide the service and most clients did not
	need the service. If service provision varied between January 1, [YEAR], and December 31, [YEAR], choose the option
	that best describes the provision of services during the <u>majority</u> of time during this period.

For each of the following safer injection and drug use supplies, please indicate the extent to which the supply was

PS1. provided. INJSUP

Safer injection and drug use supplies

Fully Partially Not Not Refuse to

	provid	ed	provided	provided but needed	provided and not needed	Answer/ Not Applicable
INJSUPA	Syringes					
INJSUPB	Cookers					
INJSUPC	Cottons					
INJSUPD	Syringe/pill filters like Sterifilt*					
INJSUPE	Saline or sterile water					
INJSUPF	Ties/tourniquets					
INJSUPG	Alcohol pads					
INJSUPH	Wound care kits					
INJSUPI	Sharps containers for carrying used syringes					
INJSUPJ	Fentanyl test strips					
INJSUPK	Safer smoking kits					
INJSUPL	Other (please describe)					
Check_PS1spec.	If R selected 'Other (please describe)' (PS1 [INJSUPL]), go to F	PS1sn	nec [INISUP	S 1		
Cilcox_i 515pcc.	Else, go to PS2 [SEXSUP].	3130	_ 100011] 556	٥].		
PS1spec. INJSUP_S	Specify other injection and drug use supplies Specify other injection and drug use supplies					
PS2.	{text response; max characters = 100} For each of the following <u>safer sex supplies</u> , please indicate t	the ex	xtent to whi	ch the suppl	y was provic	led.
SEXSUP	Safer sex supplies					
				Not	Not	
				provided	provided	
	Fully		Partially	but	and not	Refuse to
	provid	ed	provided	needed	needed	Answer
SEXSUPA	External condoms (male condoms)					
SEXSUPB	Internal condoms (female condoms)	•••••				
SEXSUPC	Lubricant					
SEXSUPD	Dental dams					
PS3. ONTEST	For each of the following <u>testing services</u> , please indicate the either by the program itself or by partners, at the location(s) Onsite testing services				=	d <u>onsite</u> ,
				Not	Not	Refuse to
			5	provided	provided	Answer/
	Fully.		Partially	but	and not	Not
ONITECT *	Fully					
ONTESTA	provid		provided	needed	needed	Applicable
ONITECTE	provid HIV rapid testing				needed	Applicable
ONTESTB	provid				needed	Applicable
ONTESTS	provid HIV rapid testing				needed	Applicable
	provid HIV rapid testing HIV laboratory-based testing				needed	Applicable

	TB skin testing or laboratory-based screening for					
0.17507.0	latent TB					
ONTEST	Pregnancy testing					
ONTEST	COVID-19 testing Other (please describe)					
ONTESTI	Other (please describe)	•••••	•••••	•		
Check_PS3spec.	If R selected 'Other (please describe)' (PS3 [ONTESTI]] Else, go to PS4 [ONVAX].	, go to PS3s	spec [ONTES]	T_S].		
PS3spec.	Specify other onsite testing service					
ONTEST_S	Specify other testing					
	{text response; max characters = 100}					
	For each of the following <u>vaccinations</u> , please indicate	a the exten	t to which th	o corvico wa	s provided a	ncita aithe
PS4.	by the program itself or by partners, at the location(s				s provided <u>o</u>	<u>iisite,</u> eitile
ONVAX	Onsite vaccinations	, where you	ai program o	peraceu.		
	Offsite vaccinations			Not	Not	Refuse to
				provided	provided	Answer/
		Fully	Partially	but	and not	Not
		provided	provided	needed	needed	Applicab
ONVAXA	Hepatitis A vaccination					
ONVAXB	Hepatitis B vaccination					
ONVAXC	Influenza vaccination					
ONVAXD	COVID-19 vaccination					
UNIVANI			•••••	•		
ONVAXE	Other (please describe)					
	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE])					
ONVAXE	Other (please describe)					
ONVAXE Check_PS4spec.	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED].					
ONVAXE Check_PS4spec. PS4spec.	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE])					
ONVAXE Check_PS4spec. PS4spec.	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination					
ONVAXE Check_PS4spec. PS4spec.	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination					
ONVAXE Check_PS4spec. PS4spec.	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination	, go to PS4s	spec [ONVAX	_s].		bed and/o
Check_PS4spec. PS4spec. ONVAX_S	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination {text response; max characters = 100}	e the extent	spec [ONVAX	_S].	-	
ONVAXE Check_PS4spec. PS4spec. ONVAX_S	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]). Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination {text response; max characters = 100} For each of the following medications, please indicates	e the extent	spec [ONVAX	_S].	-	
ONVAXE Check_PS4spec. PS4spec. ONVAX_S	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination {text response; max characters = 100} For each of the following medications, please indicated dispensed onsite, either by the program itself or by program itse	e the extent	spec [ONVAX	_S].	-	perated.
ONVAXE Check_PS4spec. PS4spec. ONVAX_S	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination {text response; max characters = 100} For each of the following medications, please indicated dispensed onsite, either by the program itself or by program itse	e the extent	spec [ONVAX	e medication s) where you Not provided	nr program o Not provided	Refuse to Answer/
ONVAXE	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination {text response; max characters = 100} For each of the following medications, please indicated dispensed onsite, either by the program itself or by program itse	e the extens	t to which th	e medication s) where you Not provided but	Not provided and not	Refuse to Answer/ Not
ONVAXE Check_PS4spec. PS4spec. ONVAX_S PS5. ONMED	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination {text response; max characters = 100} For each of the following medications, please indicated dispensed onsite, either by the program itself or by program itse	e the extent	spec [ONVAX	e medication s) where you Not provided	nr program o Not provided	Refuse to Answer/ Not
ONVAXE Check_PS4spec. PS4spec. ONVAX_S PS5. ONMED	Other (please describe) If R selected 'Other (please describe)' (PS4 [ONVAXE]) Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination {text response; max characters = 100} For each of the following medications, please indicated dispensed onsite, either by the program itself or by program itse	e the extendartners, at Fully provided	t to which the location (e medications) where you Not provided but needed	Not provided and not	perated. Refuse to Answer/
ONVAXE Check_PS4spec. PS4spec. ONVAX_S PS5. ONMED	If R selected 'Other (please describe)' (PS4 [ONVAXE]' Else, go to PS5 [ONMED]. Specify other vaccination Specify other vaccination {text response; max characters = 100} For each of the following medications, please indicated dispensed onsite, either by the program itself or by posite medications	e the extentartners, at the provided	t to which th	e medications) where you not provided but needed	Not provided and not	Refuse to Answer/ Not

ONMEDD	Hepatitis C treatment					
ONMEDE	STI treatment other than hepatitis or HIV					
ONMEDF	Medications for opioid use disorder (MOUD)					
ONMEDG	Medications for non-opioid substance use disord					
ONMEDH	Medications for mental health disorders					
ONMEDI	Other (please describe)			•		
Check_PS5spec.	If R selected 'Other (please describe)' (PS5 [ONN	MEDI]), go to PS5:	spec [ONMEI	D_S].		
	Else, go to Check_PS6.					
PS5spec.	Specify other <u>medication</u>					
ONMED_S	Specify other medication					
ONNED_3						
	{text response; max characters = 100}					
Check_PS6.	If R provided MOUD (PS5 [ONMEDF] EQ "Fully p Else, go to PS7 [ONMSRV].	provided" OR "Par	rtially provide	ed"), go to Ps	S6 [MOUD_S]	1.
PS6. MOUD_S Check_PS6spec.	You indicated that your program provided onsit [YEAR], and December 31, [YEAR]. Which of the program itself or by partners, at the location(s) Which MOUD provided Buprenorphine/naloxone (Suboxone) Buprenorphine (Subutex) Methadone Naltrexone (Vivitrol) Other (please describe) Refuse to Answer If R selected 'Other (please describe)' (PS6 [MOI Else, go to PS7 [ONMSRV].	following MOUI where your prog	O did your pr	ogram provi ed? Select all	de <u>onsite,</u> ei	·
P0/						
PS6spec. MOUD_SS	Specify other MOUD					
MOOD_SS	Specify other MOUD					
	{text response; max characters = 100}					
PS7. ONMSRV	For each of the following other medical services onsite, either by the program itself or by partne Other onsite medical services					Refuse to
		- "	D- 11 11	•		Answer/
		Fully	Partially	but	and not	Not
ONMSRVA	Substance use disorder treatment services	Fully provided	Partially provided	•		

ONMSRVB	Wound care/treatment				
ONMSRVC	Mental health services (excluding medications)				
	provided by a licensed physician, psychologist,				
	nurse practitioner, or social worker				
ONMSRVD	General medical care (primary care or urgent care)				
ONMSRVE	Reproductive health care excluding STI testing (e.g.,				
	pap smears)				
ONMSRVF	Family planning, contraception, or prenatal care				
ONMSRVG	Other (please describe)				
OTTIVIORY C	other (predict describe)				
Check_PS7spec.	If R selected 'Other (please describe)' (PS7 [ONMSRVG]), go to PS7s	spec [ONMS	SRV Sl.		
	Else, go to PS8 [CPNAV].		,		
	, ,				
PS7spec.	Specify other onsite medical services				
ONMSRV_S	Specify other onsite medical services				
_	· ,				
	{text response; max characters = 100}				
	Did your program provide client navigation services/peer navigatio	n? Client/p	oeer navigat	ion provides	;
PS8.	individualized support for program clients in accessing and sustaini	ing engagei	ment with h	ealth and ot	her services.
CPNAV	Did program provide client/peer navigation services				
	No		0		
	Yes		1		
	Refuse to Answer		7		
Check_PS9.	If R provided client/peer navigation services (PS8) [CPNAV] EQ 1), go	o to PS9 [CI	PNAV_S].		
	Else, go to PS10 [SOCSRV].				
PS9.	What services were covered by your client navigation/peer navigat	tion progra	m? Select a	I that apply.	
CPNAV_S	Client/peer navigation services				
	HIV care				
	PrEP (pre-exposure prophylaxis for HIV prevention)				
	HCV care				
	Medications for opioid use disorder (MOUD)				
	Medications for non-opioid substance use disorders				
	Legal records (e.g., birth certificate, social security card, state				
	ID/driver's license)				
	Medicaid or other health insurance				
	Social support services (e.g., housing)				
	Refuse to Answer		77		
PS10.	For each of the following <u>social and other services</u> , please indicate	the extent	to which th	e service wa	s provided.
SOCSRV	Social and other services				
			Not	Not	Refuse to
			provided	provided	Answer/
	Fully I	Partially	but	and not	Not

provided provided needed

needed Applicable

SOCSRVA	Case management
SOCSRVB	Childcare
SOCSRVC	Drop-in center
SOCSRVD	Enrollment in Medicaid or other health insurance
SOCSRVE	Family violence, domestic violence, or intimate
SOCSKVE	partner violence services
SOCSRVF	Food/meals, including SNAP, WIC, food pantries, or
	meal delivery services
SOCSRVG	Housing support
SOCSRVH	Hygiene-related services (e.g., laundry, showers)
SOCSRVI	Job-related services (e.g., placement assistance,
	skills training)
SOCSRVJ	Legal services/counseling
SOCSRVK	Substance use counseling provided by certified
	addiction counselors or other recovery support
	services
SOCSRVL	Other (please describe)
Check_PS10spec.	If R selected 'Other (please describe)' (PS10) [SOCSRVL]), go to PS10spec [SOCSRV_S].
Check_F310spec.	Else, go to INTRO_PS2.
	70 _
PS10spec.	Specify other social service
SOCSRV_S	Specify other social service
	{text response; max characters = 100}
INITED DC44	
INTRO_PS11.	
	The next questions pertain to <u>referrals</u> provided by your program between January 1, [YEAR], and December 31, [YEAR]. By "referral" we mean directing clients to specific effeite providers where they can receive specific services.
	The next questions pertain to <u>referrals</u> provided by your program between January 1, [YEAR], and December 31, [YEAR]. By "referral," we mean directing clients to specific offsite providers where they can receive specific services.
PS11.	[YEAR]. By "referral," we mean directing clients to specific offsite providers where they can receive specific services.
	[YEAR]. By "referral," we mean directing clients to specific offsite providers where they can receive specific services. What types of <u>referrals to testing services</u> did your program provide? Select all that apply.
PS11.	[YEAR]. By "referral," we mean directing clients to specific offsite providers where they can receive specific services.
PS11.	[YEAR]. By "referral," we mean directing clients to specific offsite providers where they can receive specific services. What types of referrals to testing services did your program provide? Select all that apply. Testing referrals
PS11.	[YEAR]. By "referral," we mean directing clients to specific offsite providers where they can receive specific services. What types of referrals to testing services did your program provide? Select all that apply. Testing referrals No testing referrals provided
PS11.	[YEAR]. By "referral," we mean directing clients to specific offsite providers where they can receive specific services. What types of referrals to testing services did your program provide? Select all that apply. Testing referrals No testing referrals provided
PS11.	[YEAR]. By "referral," we mean directing clients to specific offsite providers where they can receive specific services. What types of referrals to testing services did your program provide? Select all that apply. Testing referrals No testing referrals provided
PS11.	What types of referrals to testing services did your program provide? Select all that apply. Testing referrals provided
PS11.	What types of referrals to testing services did your program provide? Select all that apply. Testing referrals No testing referrals provided
PS11.	What types of referrals to testing services did your program provide? Select all that apply. Testing referrals No testing referrals provided
PS11.	What types of referrals to testing services did your program provide? Select all that apply. Testing referrals No testing referrals provided
PS11.	What types of referrals to testing services did your program provide? Select all that apply. Testing referrals No testing referrals provided
PS11.	What types of referrals to testing services did your program provide? Select all that apply. Testing referrals No testing referrals provided

Else, go to PS12 [RCOVAX].

PS11spec.	Specify other <u>testing referral</u>
REFTEST_S	Specify other testing referral
	{text response; max characters = 100}
DC4.2	What houses of unfavorals for a scientific as did as an average provide? Calent all that could
PS12.	What types of referrals for vaccinations did your program provide? Select all that apply.
REFVAX	Vaccination referral
	No vaccination referrals provided
	Hepatitis A vaccination
	Hepatitis B vaccination
	Influenza vaccination
	COVID-19 vaccination
	Other (please describe)
	Refuse to Answer
Check_PS12spec.	If R selected 'Other (please describe)' (PS12(6) [REFVAX(6)] EQ 1), go to PS12spec [REFVAX_S].
	Else, go to PS13 [REFMED].
PS12spec.	Specify other <u>vaccination referral</u>
REFVAX_S	Specify other vaccination referral
KLFVAX_3	Specify other vaccination referral
	{text response; max characters = 100}
PS13.	What types of <u>referrals to treatment</u> did your program provide? Select all that apply.
REFMED	Referrals to treatment
	No treatment referrals provided
	HIV treatment
	PrEP (pre-exposure prophylaxis)
	PEP (post-exposure prophylaxis)
	Hepatitis C treatment
	STI treatment other than hepatitis or HIV
	Buprenorphine (including Suboxone or Subutex)
	Medications for opioid use disorder (MOUD) other than
	buprenorphine
	Naloxone
	Medications for non-opioid substance use disorders
	Medications for mental health disorders
	Other (please describe)
	Refuse to Answer
	Notice to Allower
Check_PS13spec.	If R selected 'Other (please describe)' (PS13(12) [REFMED(12)] EQ 1), go to PS13spec [REFMED_S].
	Else, go to PS14 [RMSRV].
PS13spec.	Specify other treatment referral
REFMED_S	Specify other treatment referral
· · 	• ,
	{text response; max characters = 100}

PS14.	What types of referrals to other medical services did your program provide? Select all that apply.						
RMSRV	Other medical services referrals						
	No referrals to other medical services provided						
	Substance use disorder treatment services (excluding						
	medications)						
Wound care/treatment							
	Mental health services (excluding medications) provided by a						
	licensed physician, psychologist, nurse practitioner, or social						
	worker						
	General medical care (primary care or urgent care)						
	Reproductive health care excluding STI testing (e.g., pap						
	smears)						
	Family planning, contraception, or prenatal care						
	Other (please describe)						
	Refuse to Answer						
Check_PS14spec.	If R selected 'Other (please describe)' (PS14(8) [RMSRV(8)] EQ 1), go to PS14spec [RMSRV_S].						
	Else, go to INTRO_MD1.						
PS14spec.	Specify other medical services referrals						
RMSRV_S	Specify other medical services referrals						
	{text response; max characters = 100}						
	2020 MODULE						
INTRO_MD1.	Next, we would like to ask you a few questions about the services you provided in 2020.						
_							
MD1.	Did your program provide any services at <u>any time</u> between January 1, 2020, and December 31, 2020?						
OP20	Operated during 2020						
	No						
	Yes						
Check_MD1.	If R did not operate at any time during 2020 (MD1 [OP20] EQ 0), go to INTRO_PE.						
CHCCK_IVID1.	Else, go to INTRO MD2.						
	EIGE, 50 to INTINO_PIDE.						
INTRO_MD2.	The next set of questions is about the services your program provided from January 1, 2020, to December 31, 2020.						
	To the extent possible, please refer to your records to answer these questions. If your program only operated during						
	some of this time period, please provide information reflective of the time period(s) during which your program did						
	operate.						

provide the best estimate to your knowledge. If you do not know or prefer not to answer, you response blank.				
CLI20	Number of unique clients			
	Range			
	Between January 1, 2020, and December 31, 2020, how many total sterile syringes did your program provide to			
	clients? Please provide your best estimate if records are not readily available. If you do not know or prefer not to			
MD3.	answer, you may leave the response blank.			
SYR20	Number of sterile syringes provided			
	Between January 1, 2020, and December 31, 2020, did your program provide syringes to clients based on the			
MD4.	clients' needs, without any restrictions?			
NEED20	Needs-based provision of syringes			
	No			
	Yes			
	Don't Know			
	Refuse to Answer/			
MD5.	Did your program distribute naloxone kits between January 1, 2020, and December 31, 2020?			
ONNAL20	Onsite naloxone distribution			
	No 0			
	Yes			
	Don't Know			
	Refuse to Answer			
	What was your total program budget between January 1, 2020, and December 31, 2020? If your program is part of			
	a larger, multi-service organization, please only provide the budget for your part of the program. Please provide			
MD6.	the best estimate to your knowledge.			
BUDG20	Total program budget			
	Less than \$25,0001			
	\$25,000-\$100,000			
	\$100,001-\$250,000			
	\$250,001-\$500,000			
	\$500,001-\$1 million			
	Between \$1 million and \$2 million			
	Don't Know			
	Refuse to Answer			
	Which of the following <u>testing services</u> were provided <u>onsite</u> , either by the program itself or by partners, at the			
MD7.	location(s) where your program operated between January 1, 2020, and December 31, 2020? Select all that apply.			
ONTST20	Onsite testing services			
	No testing services were provided onsite			
	HIV rapid testing			

HIV laboratory-based testing.....

	Hepatitis C virus (HCV) rapid testing Hepatitis C virus (HCV) laboratory-based testing
	Refuse to Answer
	Which of the following medications for opioid use disorder (MOUD) were provided onsite, either by the program itself or by partners, at the location(s) where your program operated between January 1, 2020, and December 31,
MD8.	2020? Select all that apply.
ONMOUD20	Onsite MOUD
	No medications were provided onsite
	Buprenorphine (Subutex)
	Methadone
	Naltrexone (Vivitrol)
	Other (please describe)
	Don't Know99
	Refuse to Answer
Check_MD8spec.	If R selected 'Other (please specify)' (MD8(6) [ONMOUD20(6)] EQ 1), go to MD8spec [ONMOUD20_S]. Else, go to MD9[ONMSRV20].
	Else, go to MD7[ONMSRV20].
MD8spec.	Specify other MOUD provided onsite.
ONMOUD20_S	Specify other MOUD
	{text response; max characters = 100}
	Which of the fellowing other modical comices were unsuited assistantial by the management itself on hy neutrons of
	Which of the following <u>other medical services</u> were provided <u>onsite</u> , either by the program itself or by partners, at the location(s) where your program operated between January 1, 2020, and December 31, 2020? Select all that
MD9.	apply.
ONMSRV20	Onsite other medical services
	No other medical services were provided onsite
	Substance use disorder treatment services (excluding
	medications)
	Wound care/treatment
	Mental health services (excluding medications) provided by a
	licensed physician, psychologist, nurse practitioner, or social
	worker
	General medical care (primary care or urgent care)
	Reproductive health care excluding STI testing (e.g., pap
	smears)
	Family planning, contraception, or prenatal care
	Don't Know
	KEIUSE LO AIISWEI//
	Did your program provide referrals for buprenorphine (including Suboxone or Subutex) between January 1, 2020,
MD10.	and December 31, 2020?
RFBUP20	Referrals to buprenorphine
	No

	Yes 1
	Don't Know 9
	Refuse to Answer 7
	Between January 1, 2020, and December 31, 2020, what types of <u>referrals to other medical services</u> did your
MD11.	program provide? Select all that apply.
RMSRV20	Other medical services referrals
	No referrals to other medical services provided
	Substance use disorder treatment services (excluding
	medications)
	Wound care/treatment
	Mental health services (excluding medications) provided by a
	licensed physician, psychologist, nurse practitioner, or social worker
	General medical care (primary care or urgent care)
	Reproductive health care excluding STI testing (e.g., pap
	smears) Family planning, contraception, or prenatal care
	Don't Know99
	Refuse to Answer
	Keluse to Aliswel
MD12. COV20	How was your program impacted by the COVID-19 pandemic in 2020? Select all that apply. COVID-19 impacts Reduced hours or days of operation
	Reduced funding
	Site closure(s)
	Staff shortage or loss
	Change to a MORE restrictive syringe distribution model (e.g.,
	from needs-based to 1-for-1)
	Change to a LESS restrictive syringe distribution model (e.g.,
	from 1-for-1 to needs-based)
	Changes in physical space (e.g., moved services outdoors,
	markers for social distancing, plexiglass)
	Disruptions in supply of syringes
	Disruptions in other supplies
	Disruptions in HIV, HCV, or other bloodborne pathogens
	testing
	Disruptions in substance use disorder treatment linkage (e.g.,
	stopped services, new regulatory practices)
	Changes in other direct client services, such as food
	distribution, showers, housing assistance
	New/increased access to telehealth for clients
	Lack of personal protective equipment (PPE)
	Other (please specify)
	Program was not impacted by COVID-19 in 2020
	Don't Know99
	Refuse to Answer 77

Check_MD12spec. If R selected 'Other (please specify)' (MD12(15) [COV20(15)] EQ 1), go to MD12spec [COV20_S]. Else, go to INTRO_PE.

MD12spec. Specify other ways your program was impacted by COVID-19.						
COV20_S	Specify other program operator					
{text response; max characters = 100}						
	PROCESS EVALUATION					
INTRO_PE.	We value your input and would like to ask you a few questions about your experience taking this survey so that we can improve it and ensure that the information you provide is useful.					
PE1.	The length of the survey was					
SLNGTH	Survey length					
SENGIII	Too short					
	Just right					
	Too long 3					
	Refuse to Answer					
DEO	16 very very deline the sympos easing what formed would very must ov? Calcut and very					
PE2. PREFMT	If you were taking the survey again, what format would you prefer? Select only one. Preferred survey format					
PREFIVII	Self-administered online 1					
	Self-administered via an electronic document (Word or PDF)					
	that can be completed and returned by email					
	Interviewer-administered to me over the phone					
	Interviewer-administered to me in person					
	Refuse to Answer					
PE3. MISTOP	What topic(s) were missing from this survey and need to be added in the future? Missing topics					
	{text response; max characters = 255}					
DE 4	Harry and the state of the stat					
PE4. HOWUSE	How would you like to see this information used? Select all that apply. How this information used					
HOWUSE	Increase awareness					
	Increase community support					
	Increase funding					
	Inform policy/law					
	Other (please describe)					
	Refuse to Answer					
Check_PE4spec.	If R selected 'Other (please describe)' (PE4(5) [HOWUSE(5)] EQ 1), go to PE4spec [HOWUSE_S]. Else, go to PE5 [OTHSUG].					

PE4spec.	Specify other use for this information					
HOWUSE_S	Specify other use for this information					
	{text response; max characters = 100}					
PE5. OTHSUG	Please use the space below for any other suggestions or comments for improving this survey to make it useful to programs. Other suggestions or comments					
011300	Other suggestions of comments					
	{text response; max characters = 255}					
DATA_PE.	You have now completed the survey. Thank you so much for your participation. Once you submit your survey, you will not be able to go back to previous questions or change any of your answers, so please make sure you are ready before proceeding.					
	Before we end, we would like to document your preference on how information about your program is shared with others aside from the survey team. Others could include, for example, researchers, health department staff, and other syringe services programs. The survey team includes staff at the North American Syringe Exchange Network (NASEN), the University of Washington (UW), New York University (NYU), and the Centers for Disease Control and Prevention (CDC). As a reminder, data from this survey will <u>only</u> be reported in aggregate (that is, your responses will be grouped with those from other programs) in formats like presentations, publications and reports. Program names and any other information that could potentially identify a program, such as the state or county where a program operates, will <u>never</u> be reported.					
PE6. DATASHR	Would you be willing to share your data with others aside from the survey team? Please remember that identifying information will never be reported. Individual data sharing preference No, data cannot be shared					
	Yes, data can be shared					
CALC_EDATE	Automatic, hidden variable: Interview end date (today)					
EDATE	End date					
	//					
CALC_END	End time of interview					
END	End time					
	:					